Read this company snapshot
Daily valuation snapshot
InflaRx N.V. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.6
- Market capitalization (USD)
- $235,789,153.6
- Price / earnings (TTM)
- Not reported
- Price / book
- 4.84
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research IFRX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research IFRX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing IFRX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.6 |
| Market capitalization (USD) | $235,789,153.6 |
| Price / earnings (TTM) | Not reported |
| Price / book | 4.84 |
No matching rows. Clear the filter to see all records.
Read IFRX's valuation metrics
Company size
InflaRx N.V. Common Stock's recorded market capitalization is $235,789,153.6. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
IFRX's recorded price-to-book ratio is 4.84. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research InflaRx N.V. Common Stock with Aurora
Use the snapshot above to ask a specific question about IFRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow IFRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.